[go: up one dir, main page]

WO2009057569A1 - フィルムコーティング製剤 - Google Patents

フィルムコーティング製剤 Download PDF

Info

Publication number
WO2009057569A1
WO2009057569A1 PCT/JP2008/069487 JP2008069487W WO2009057569A1 WO 2009057569 A1 WO2009057569 A1 WO 2009057569A1 JP 2008069487 W JP2008069487 W JP 2008069487W WO 2009057569 A1 WO2009057569 A1 WO 2009057569A1
Authority
WO
WIPO (PCT)
Prior art keywords
film
coated preparation
disclosed
coated
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/069487
Other languages
English (en)
French (fr)
Inventor
Takeshi Hamaura
Susumu Hasegawa
Ikumasa Ohno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Priority to JP2009539054A priority Critical patent/JPWO2009057569A1/ja
Priority to CN200880114044A priority patent/CN101842096A/zh
Publication of WO2009057569A1 publication Critical patent/WO2009057569A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

薬剤の有する臭いを低減できるフィルムコーティング製剤を提供する。 処方中にオルメサルタンメドキソミルを含有し、フィルム層中にポリビニルアルコール又はビニルアルコール系共重合体を含有するフィルムコーティング製剤。
PCT/JP2008/069487 2007-10-29 2008-10-28 フィルムコーティング製剤 Ceased WO2009057569A1 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2009539054A JPWO2009057569A1 (ja) 2007-10-29 2008-10-28 フィルムコーティング製剤
CN200880114044A CN101842096A (zh) 2007-10-29 2008-10-28 薄膜包衣制剂

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-280843 2007-10-29
JP2007280843 2007-10-29

Publications (1)

Publication Number Publication Date
WO2009057569A1 true WO2009057569A1 (ja) 2009-05-07

Family

ID=40590960

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/069487 Ceased WO2009057569A1 (ja) 2007-10-29 2008-10-28 フィルムコーティング製剤

Country Status (5)

Country Link
JP (1) JPWO2009057569A1 (ja)
KR (1) KR20100072317A (ja)
CN (1) CN101842096A (ja)
TW (1) TW200927197A (ja)
WO (1) WO2009057569A1 (ja)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011025035A1 (ja) * 2009-08-31 2011-03-03 日新化成株式会社 コーティング用組成物
JP2012193175A (ja) * 2011-03-02 2012-10-11 Daiichi Sankyo Healthcare Co Ltd 速溶性防湿フィルムコーティング製剤及びその製造方法
EP2594277A4 (en) * 2010-07-07 2014-01-01 Japan Tobacco Inc TABLET WITH IRON CITRATE
WO2014080365A1 (en) * 2012-11-23 2014-05-30 Ranbaxy Laboratories Limited Method of reducing an unpleasant odor of a pharmaceutical composition
WO2014188728A1 (ja) * 2013-05-24 2014-11-27 持田製薬株式会社 フィルムコーティング用組成物
EP2830618A4 (en) * 2012-03-30 2015-08-05 Dae Woong Pharma PHARMACEUTICAL COMPOSITION WITH OLMESARTAN MEDOXOMIL AND ROSUVASTATIN OR ITS SALT
JP2016141630A (ja) * 2015-01-30 2016-08-08 富士フイルム株式会社 口腔内崩壊錠
JP2017001999A (ja) * 2015-06-12 2017-01-05 富士フイルム株式会社 薬物含有粒子の製造方法、薬物含有粒子、医薬組成物、及び口腔内崩壊錠
WO2017164208A1 (ja) * 2016-03-24 2017-09-28 第一三共株式会社 腎疾患の治療のための医薬

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102716100B (zh) * 2012-07-12 2013-08-07 南京正大天晴制药有限公司 一种含奥美沙坦酯的片剂及其制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002179741A (ja) * 2000-10-04 2002-06-26 Basf Ag ヒドロキシアルキル（メタ）アクリレートの水溶性または水分散性（コ）ポリマー、その製造方法、ならびに医薬投与剤形における被覆剤、結合剤および／またはフィルム形成性賦形剤としてのその使用
WO2005019286A1 (ja) * 2003-08-20 2005-03-03 Shionogi & Co., Ltd. 新規コーティング組成物
WO2006123766A1 (ja) * 2005-05-20 2006-11-23 Daichi Sankyo Company, Limited デキストロース含有フィルムコーティング製剤
WO2006123765A1 (ja) * 2005-05-20 2006-11-23 Daiichi Sankyo Company, Limited フィルムコーティング製剤
JP2007091620A (ja) * 2005-09-28 2007-04-12 Kyoto Pharmaceutical Industries Ltd フィルムコーティング錠剤
JP2007197410A (ja) * 2006-01-30 2007-08-09 Lion Corp フィルムコーティング錠

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002179741A (ja) * 2000-10-04 2002-06-26 Basf Ag ヒドロキシアルキル（メタ）アクリレートの水溶性または水分散性（コ）ポリマー、その製造方法、ならびに医薬投与剤形における被覆剤、結合剤および／またはフィルム形成性賦形剤としてのその使用
WO2005019286A1 (ja) * 2003-08-20 2005-03-03 Shionogi & Co., Ltd. 新規コーティング組成物
WO2006123766A1 (ja) * 2005-05-20 2006-11-23 Daichi Sankyo Company, Limited デキストロース含有フィルムコーティング製剤
WO2006123765A1 (ja) * 2005-05-20 2006-11-23 Daiichi Sankyo Company, Limited フィルムコーティング製剤
JP2007091620A (ja) * 2005-09-28 2007-04-12 Kyoto Pharmaceutical Industries Ltd フィルムコーティング錠剤
JP2007197410A (ja) * 2006-01-30 2007-08-09 Lion Corp フィルムコーティング錠

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011025035A1 (ja) * 2009-08-31 2011-03-03 日新化成株式会社 コーティング用組成物
JP5730205B2 (ja) * 2009-08-31 2015-06-03 日新化成株式会社 コーティング用組成物
EP2594277A4 (en) * 2010-07-07 2014-01-01 Japan Tobacco Inc TABLET WITH IRON CITRATE
JP2012193175A (ja) * 2011-03-02 2012-10-11 Daiichi Sankyo Healthcare Co Ltd 速溶性防湿フィルムコーティング製剤及びその製造方法
EP2830618A4 (en) * 2012-03-30 2015-08-05 Dae Woong Pharma PHARMACEUTICAL COMPOSITION WITH OLMESARTAN MEDOXOMIL AND ROSUVASTATIN OR ITS SALT
WO2014080365A1 (en) * 2012-11-23 2014-05-30 Ranbaxy Laboratories Limited Method of reducing an unpleasant odor of a pharmaceutical composition
WO2014188728A1 (ja) * 2013-05-24 2014-11-27 持田製薬株式会社 フィルムコーティング用組成物
JPWO2014188728A1 (ja) * 2013-05-24 2017-02-23 持田製薬株式会社 フィルムコーティング用組成物
JP2016141630A (ja) * 2015-01-30 2016-08-08 富士フイルム株式会社 口腔内崩壊錠
JP2017001999A (ja) * 2015-06-12 2017-01-05 富士フイルム株式会社 薬物含有粒子の製造方法、薬物含有粒子、医薬組成物、及び口腔内崩壊錠
WO2017164208A1 (ja) * 2016-03-24 2017-09-28 第一三共株式会社 腎疾患の治療のための医薬

Also Published As

Publication number Publication date
CN101842096A (zh) 2010-09-22
KR20100072317A (ko) 2010-06-30
TW200927197A (en) 2009-07-01
JPWO2009057569A1 (ja) 2011-03-10

Similar Documents

Publication Publication Date Title
WO2009057569A1 (ja) フィルムコーティング製剤
WO2008100375A3 (en) Polymer-based films and drug delivery systems made therefrom
WO2010022154A3 (en) Release materials
MX2009010690A (es) Metodo y composición para aislamiento de zonas de un pozo.
WO2011084593A3 (en) Abuse-resistant formulations
WO2010037728A3 (en) Formulations comprising ezetimibe
CR20110072A (es) Sistema de administración de drogas que contiene progestina
WO2011031558A3 (en) Toughened polyhydroxyalkanoate compositions
WO2010026433A3 (en) Polymeric material
WO2009023662A3 (en) Water-resistant, rub-resistant, sprayable, homogeneous sunscreen composition
WO2009129301A3 (en) Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas
MX2009005445A (es) Sistema de suministro para risperidona.
WO2007095600A3 (en) Disintegrable oral films
GEP20125410B (en) Solid preparation comprising alogliptin and pioglitazone
WO2006023444A3 (en) Anti-adhesion barrier
WO2007149958A3 (en) Superthin wound dressing having folded release sheet
PE20091574A1 (es) Sistema de administracion de drogas con efecto estabilizante
WO2011101866A3 (en) Gastric retention formulation containing baclofen
AU2007338403A1 (en) shRNA-mediated inhibition of expression of alpha-1. 6-fucosyltransferase
WO2008093648A1 (ja) 樹脂組成物及び多層構造体
WO2009076272A3 (en) Drug coated stent with endosome-disrupting conjugate
WO2007080172A3 (en) Plasticizer of natural origin for nail polish
WO2008078727A1 (ja) 溶出性の改善された医薬組成物
MX2009005446A (es) Sistema de suministro vaginal para mirtazapina.
UA102680C2 (ru) Единичная дозированная форма, которая включает привитый сополимер поливинилового спирта-полиэтиленгликоля и стероидный эстроген

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880114044.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08845153

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009539054

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 20107009312

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08845153

Country of ref document: EP

Kind code of ref document: A1